Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
UPTRAVI vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Uptravi (selexipag) is a prostacyclin receptor (IP receptor) agonist. Selexipag and its active metabolite, ACT-333679, selectively bind to the IP receptor, leading to vasodilation, inhibition of platelet aggregation, and antiproliferative effects on smooth muscle cells.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization,Off-label: None established
Management of mild to moderate pain,Reduction of fever
Initial dose 200 mcg orally twice daily, titrated in increments of 200 mcg twice daily at weekly intervals to a maximum of 1600 mcg twice daily.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life is approximately 7–9 hours in healthy subjects, but prolonged in patients with hepatic impairment (Child-Pugh class A: ~11 hours; class B: ~16 hours). Steady-state is reached within 2–4 days of twice-daily dosing.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Selexipag is hydrolyzed by carboxylesterases (mainly CES1 and CES2) to its active metabolite, ACT-333679. Both are further metabolized by CYP3A4 and CYP2C8. ACT-333679 is also a substrate for UGT1A3 and UGT2B7.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily hepatic metabolism; renal excretion of unchanged drug is <1%. Fecal excretion accounts for approximately 70% of total elimination, mainly as metabolites. Biliary excretion contributes to fecal elimination.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
99% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
10-25% bound to albumin at therapeutic concentrations.
Approximately 0.3 L/kg in healthy subjects, indicating distribution primarily within the vascular space and well-perfused tissues.
0.8-1.0 L/kg; suggests distribution into total body water.
Oral bioavailability is approximately 50–60% due to first-pass metabolism. Food does not significantly affect absorption.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥15 m L/min/1.73 m²). Not studied in severe renal impairment (e GFR <15 m L/min/1.73 m²) or on dialysis; use caution.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Mild hepatic impairment (Child-Pugh A): No dose adjustment. Moderate hepatic impairment (Child-Pugh B): Initial dose 200 mcg once daily, titrate cautiously. Severe hepatic impairment (Child-Pugh C): Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Not indicated for pediatric patients; safety and efficacy not established in patients <18 years.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
No specific dose adjustment recommended; elderly patients may have increased sensitivity, monitor closely.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
None.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Pulmonary edema may occur; consider the possibility of pulmonary veno-occlusive disease (PVOD) if symptoms develop,Hepatic impairment: Avoid use in severe hepatic impairment (Child-Pugh Class C),Concomitant use with strong CYP2C8 inhibitors (e.g., gemfibrozil) increases exposure; reduce dose or consider alternative,Concomitant use with strong CYP3A4 inducers (e.g., rifampin) may reduce efficacy; monitor for loss of effect
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Severe hepatic impairment (Child-Pugh Class C),Concomitant use with strong CYP2C8 inhibitors (e.g., gemfibrozil)
Hypersensitivity to acetaminophen or any component of the formulation
Avoid grapefruit juice as it may increase systemic exposure to UPTRAVI. Take with or without food, but consistent timing with meals is recommended to maintain stable drug levels.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
In animal studies, UPTRAVI (selexipag) and its active metabolite showed developmental toxicity including reduced fetal weights and increased skeletal variations at maternal toxic doses. No adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. First trimester: potential teratogenicity based on animal data. Second and third trimesters: may cause fetal harm due to pharmacological action (IP receptor agonist) potentially affecting uterine blood flow.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio is unknown. The active metabolite is potentially excreted in animal milk. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 days after final dose.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No pharmacokinetic studies in pregnant women. Pregnancy may alter drug metabolism (e.g., increased clearance, Vd). No specific dose adjustment recommendations; use only if benefit outweighs risk. Close clinical monitoring for efficacy and tolerability.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Titrate to maximum tolerated dose up to 1600 mg twice daily. Monitor for signs of pulmonary edema (PPH with veno-occlusive disease). Co-administration with strong CYP2C8 inhibitors (e.g., gemfibrozil) reduces UPTRAVI clearance; decrease dose by 50% during co-administration. Avoid abrupt discontinuation; taper if possible. May cause orthostatic hypotension; assess blood pressure regularly. UPTRAVI is a prodrug of the active metabolite ACT-333679, a selective prostacyclin receptor (IP receptor) agonist.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take exactly as prescribed; do not crush or split tablets.,Do not stop taking this medication suddenly; consult your doctor if you need to discontinue.,Avoid grapefruit juice as it may increase drug exposure.,Report any severe headaches, jaw pain, or flushing to your healthcare provider.,Use caution when driving or operating machinery until you know how this medication affects you.,Store at room temperature away from moisture and heat.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about UPTRAVI vs INJECTAPAP, answered by our medical review team.
UPTRAVI is a Prostacyclin Receptor Agonist that works by Uptravi (selexipag) is a prostacyclin receptor (IP receptor) agonist. Selexipag and its active metabolite, ACT-333679, selectively bind to the IP receptor, leading to vasodilation, inhibition of platelet aggregation, and antiproliferative effects on smooth muscle cells.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between UPTRAVI and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of UPTRAVI is: Initial dose 200 mcg orally twice daily, titrated in increments of 200 mcg twice daily at weekly intervals to a maximum of 1600 mcg twice daily.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between UPTRAVI and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. UPTRAVI is classified as Category C. In animal studies, UPTRAVI (selexipag) and its active metabolite showed developmental toxicity including reduced fetal weights and increased skeletal variations at maternal toxic d. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.